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ABSTRACT 
Although dementia with Lewy bodies (DLB) is a synucleinopathy, it is frequently accompanied by β-amyloid 
accumulation (Aβ). Elucidating the relationships of Aβ with grey matter atrophy in DLB may yield insights 
regarding the contributions of comorbid Alzheimer’s disease to its disease progression. Twenty healthy 
controls and twenty-five DLB subjects underwent clinical assessment, [18F]-Florbetapir and 3T MRI. 
Freesurfer was used to estimate cortical thickness and subcortical volumes and PetSurfer was used to 
quantify [18F]-Florbetapir standardised uptake value ratio. Principal component analysis was used to 
identify the dominant Aβ component for correlations with regional cortical thickness, hippocampal 
subfields and subcortical structures. Relative to healthy controls, the DLB group demonstrated increased 
Aβ in widespread regions encompassing the frontal and temporo-parietal cortices, whereas cortical 
thinning was restricted to the temporal lobe. Amongst DLB subjects, the Aβ component was significantly 
associated with more severe hippocampal and subiculum atrophy. These findings may reflect an early 
process of superimposed AD-like atrophy in DLB, thereby conferring support for the therapeutic potential 
of anti-Aβ interventions in people with DLB. 
KEYWORDS: Dementia with Lewy bodies, Alzheimer’s disease, amyloid, PET, MRI. 
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1. INTRODUCTION 
Dementia with Lewy bodies (DLB) is the second most common degenerative form of dementia in elderly 
people after Alzheimer’s disease (AD) (McKeith et al., 2017). Although alpha-synucleinopathy is recognised 
as the key neuropathological hallmark of DLB, up to 80% of people with DLB show varying degrees of AD 
pathologies – beta-amyloid (Aβ) and neurofibrillary tau tangles (NFTs) – at autopsy (Colom-Cadena et al., 
2013; McKeith et al., 2017, 2005). The advent of PET amyloid ligands has offered unique opportunities for 
the ante-mortem quantification of Aβ burden and how it relates to clinical and neuroimaging abnormalities 
associated with preclinical and established AD (Chetelat et al., 2013; see Habib and Mak et al., 2017 for a 
systematic review). However, it remains unclear if and to what extent Aβ contributes to the disease progression 
and neurodegenerative changes in DLB (see Donaghy et al., 2015 for a systematic review). This knowledge 
gap is unfortunate, since new insights concerning the impact of Aβ in DLB could have long-term ramifications 
on treatment strategies as well as monitoring outcomes in emerging trials that specifically target the 
aggregation of Aβ (Sperling et al., 2014). 
 
The ‘Aβ cascade hypothesis’ in AD posits an initiating event of amyloidosis, with subsequent tau 
accumulation preceding downstream brain atrophy and cognitive decline (Hardy, 2002). This AD spatio-
temporal model of disease progression has been central to the recent shift towards disease-modification 
strategies (Sperling et al., 2014), although its relevance to DLB is still controversial (Donaghy et al., 2015). 
For instance, limited evidence suggests a modest association of Aβ with cognitive decline and increased 
mortality risks (Gomperts, 2014), although others have reported no association with dementia severity in DLB 
(Shimada et al., 2013). The discordant findings may, in part, stem from the inherent challenges of 
psychometric assessments such as mood changes, fatigue and attentional impairments, all of which could be 
exacerbated by cognitive fluctuations in DLB patients. In contrast, particularly in the context of AD, brain 
atrophy is increasingly proposed as a reliable biomarker of disease progression (Sluimer et al., 2008) and 
secondary outcome measure in clinical trials (Cash et al., 2015; Schott et al., 2010; Slattery et al., 2015). 
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Widely understood to be one of endpoints in the neurodegenerative cascade (Jack et al., 2013), brain atrophy 
has been extensively studied in relation to upstream Aβ across the spectrum of normal ageing, mild cognitive 
impairment and AD (Chetelat et al., 2010; Josephs et al., 2008). Surprisingly, this question has been scarcely 
addressed in DLB (Shimada et al., 2013; Sarro et al., 2016; see Table 1 for main findings). 
 
A voxel-based morphometry (VBM) analysis reported a stereotypical AD pattern of parahippocampal atrophy 
in a small sample of antecedent Aβ-positive patients with Lewy body dementia (Shimada et al., 2013). This 
observation is broadly consistent with another longitudinal study, where higher baseline levels of global [11C]-
PiB binding were associated with higher rates of atrophy in the medial temporal lobe and other cortical regions 
in DLB over 2 years (Sarro et al., 2016). In both studies, the authors interpreted their findings to suggest that 
people with DLB may stand to benefit from anti-amyloid therapies should such treatments be available and 
safe. However, the sample size was rather small in both studies and no controls were recruited (Sarro et al., 
2016) Finally, no study has evaluated the relationships of Aβ burden with hippocampal subfields. Post-mortem 
investigations have demonstrated that hippocampal atrophy in AD is non-uniform, with preferential 
vulnerability of the cornu ammonis 1 (CA1) and subiculum atrophy in early AD (Braak and Braak, 1991; 
West et al., 1994). Therefore, understanding how Aβ relates to hippocampal subfields may provide novel 
insights about the pathological underpinnings of early AD-type atrophy in people with DLB. To these ends, 
automated techniques have been validated to perform segmentation of hippocampal subfields from structural 
MRI data (Wisse et al., 2014; Iglesias et al., 2015; Yushkevich al., 2015). We and others have previously 
applied the Freesurfer technique to demonstrate differential hippocampal subfield atrophy in DLB and AD 
(Chow et al., 2012; Mak et al., 2016), achieving very similar findings compared to our manual tracing work 
(Firbank et al., 2010). 
 
To extend these promising investigations and clarify the topography of Aβ-associated atrophy patterns in 
DLB, we performed a PET-CT and structural MRI study with the following key aims: (a) To compare and 
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contrast the spatial profiles of abnormal Aβ accumulation and cortical thinning in DLB relative to healthy 
controls; (b) To determine the global overlap between Aβ binding and cortical thinning, and (c) To delineate 
the associations of a data-driven composite measure of Aβ burden with regional cortical thickness, 
hippocampal subfield other subcortical structures. 
 
2. METHODS 
2.1. Participants 
Participants were recruited prospectively between June 2013 and February 2016 from secondary care services 
in the North of England. Control subjects were recruited through a research case register or were partners of 
participants. All subjects were ≥ 60 years old. Dementia subjects had a diagnosis of probable DLB confirmed 
by two clinicians based on current diagnostic criteria with an MMSE ≥ 12. Results of amyloid imaging were 
not known to the clinicians when making the diagnosis. Control subjects had an MMSE ≥ 26 and no signs of 
dementia. DLB subjects were recruited prior to the publication of the 2017 diagnostic criteria for DLB, 
however, they would satisfy the updated criteria for probable DLB (McKeith et al., 2017). Subjects were 
excluded if they had a major concurrent psychiatric illness; severe physical illness; contraindications to PET-
CT imaging; a history of other significant neurological illness including stroke; previous experimental 
treatment with an amyloid-targeting agent or current treatment with any other investigational agent. Subjects 
with capacity gave their written informed consent to take part in the study. For those with dementia who lacked 
capacity, their participation in the study was discussed with a consultee in accordance with the Mental 
Capacity Act. The study received ethical approval from the National Research Ethics Service Committee 
North East - Newcastle & North Tyneside 2 (Research Ethics Committee Identification Number 13/NE/0064). 
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2.2. Baseline cognitive and clinical assessment  
The DLB sample underwent clinical and cognitive assessments, including the Addenbrooke’s Cognitive 
Examination-Revised (ACE-R) and the Revised Unified Parkinson’s disease Rating Scale Motor Sub-scale 
(UPDRS).  
 
2.3. Structural MRI 
Scans were acquired on a 3T whole body MR scanner (Achieva scanner; Philips Medical Systems), with body 
coil transmission and eight channel head coil receiver. Images acquired included a 3D sagittal magnetisation-
prepared rapid gradient echo (MPRAGE) sequence (repetition time 8.3ms, echo time 4.6ms, flip angle 8o, 
inversion delay 1250 ms, imaging time 4.5mins). The sagittal acquisition matrix was 216x240, giving a voxel 
size of 1x1x1mm. The T1-MPRAGE data were processed using Freesurfer version 6 to obtain cortical 
thickness measurements in 34 ROIs per hemisphere, based on the Desikan-Killiany parcellation scheme 
(Desikan et al., 2006). The technical details for the quantification of cortical thickness have been extensively 
described (Fischl and Dale, 2000). Briefly, for each T1-MPRAGE data, the pial and white matter surfaces 
were generated and the cortical thickness was measured as the distance between the boundaries of pial and 
white matter surfaces. Visual inspection was carried by two operators (EM and EMc) while blinded to group 
diagnostic information, and corrections were performed to ensure accurate skull-stripping, placement of 
control points and reconstruction of white matter and pial surfaces. Five DLB subjects were excluded in the 
process. The cortical thickness maps were smoothed using a Gaussian kernel across the surface with a full 
width at half maximum (FWHM) of 15mm. In addition, the volumetric pipeline of Freesurfer was used to 
estimate the total intracranial volumes (ICV), as well as the subcortical deep grey matter regions: thalamus, 
nucleus accumbens, amygdala, pallidum, putamen, caudate and the hippocampus. Hippocampal subfield 
volumes were estimated using Freesurfer. Briefly, this automated technique uses a probabilistic atlas built 
upon ultra-high resolution ex MRI data (Iglesias et al., 2015). Compared to its previous version (Van Leemput 
et al., 2009), the ultra-high resolution of the ex vivo MRI training data provided a better contrast between the 
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subfield boundaries, thus improving the reliability of the subfield annotations. As a result, the subfield 
volumes estimated from this technique yielded better agreement with those from histological studies (Iglesias 
et al., 2015). To facilitate the integration of PET and MRI data, we used the PetSurfer tool to segment 
additional regions from the T1 MRI data, such as the cerebral CSF, pons, skull and air cavities. These 
additional segmentations were merged with the default Freesurfer segmentations to provide anatomical 
information for partial-volume correction (PVC) described below (Greve et al., 2014). 
 
2.4. PET imaging 
PET-CT imaging was performed using a Siemens Biograph-40 PET-CT scanner. Subjects had a 15-minute 
scan 30-50 minutes after a 370MBq intravenous injection of [18F]-Florbetapir (Amyvid). PET images were 
reconstructed using iterative reconstruction (4 iterations, 16 subsets), with a 168 x 168 matrix size, 2.04 x 2.04 
mm pixel size, 3 mm slice thickness, and 3 mm post-reconstruction Gaussian filter. Attenuation correction 
was performed utilising CT scan data obtained immediately before the PET images, and reconstructed with 3 
mm slice thickness to match the PET images. To perform PVC, each frame of the [18F]-Florbetapir data was 
realigned with statistical parametric mapping (SPM) and averaged. The resultant mean images were 
coregistered to their native T1 MRI data and the accuracy of the PET-MRI registration was inspected for each 
subject. Consistent with previous studies (Greve et al., 2016; LaPoint et al., 2017), the Symmetric Geometric 
Transfer Matrix (SGTM) technique was implemented to derive PVC-ROIs after the Freesurfer segmentations 
were transformed back into the PET native space. Subsequently, the standardised uptake ratios (SUVRs) were 
obtained for each region by normalisation against the cerebellar cortex. Notably, this approach in Freesurfer 
has been demonstrated to show an excellent agreement of PET regional quantification with manually defined 
regions (Su et al., 2013). As the SGTM technique is strictly designed for PVC of ROI data, we used the Muller-
Gartner technique to perform PVC on vertex-wise [18F]-Florbetapir data (Greve et al., 2014). The corrected 
vertex-wise PET data were then sampled onto the cortical surface and smoothed using a FWHM of 4 mm. By 
restricting the smoothing along the cortical ribbon, we further account for the contamination of [18F]-
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Florbetapir signal due to contributions from the white matter, CSF or adjacent grey matter regions that are 
highly proximal in Euclidean space. Compared to volumetric methods, the surface-based PET framework is 
increasingly advocated for parametric comparisons as it has been associated with reductions of inter-subject 
variance, and higher reliability across different tracers and PET systems (Greve et al., 2014; Matheson et al., 
2017).  
 
2.5. Statistical analyses 
Statistical analyses were performed in MATLAB 2017A and the R statistical package. The specific analyses 
catering to each of our primary objectives are detailed as follows: To characterise the spatial distribution of 
increased Aβ and cortical thinning in DLB, both vertex-wise [18F]-Florbetapir PET and cortical thickness data 
were compared between the DLB and healthy controls using the general linear model in Freesurfer, and were 
adjusted for age and corrected for multiple comparisons using the cluster-wise method. The vertex-wise 
threshold, otherwise referred to as the cluster-forming threshold was set at 0.001, while significance for 
clusters were set p < 0.05). Next, using a ROI-based approach, we explored the inter-regional correlation 
between [18F]-Florbetapir SUVR and cortical thickness (i.e. 68 ROIs per modality) with linear mixed effect 
models using the lme4 package in R (Bates et al., 2015). Specifically, cortical thickness was assigned as the 
dependent variable, with [18F]-Florbetapir SUVR ROIs as fixed factors, allowing for random intercepts across 
subjects and cortical lobes (i.e. frontal, occipital, parietal and temporal lobes) so as to account for the inter-
dependency resulting from repeated measurements per subject (i.e. 68 ROIs per subject). The statistical 
significance of the relationships was assessed using the likelihood ratio test by comparing the fit between the 
full linear mixed effect model and a reduced model (i.e. without the fixed effect of 18F]-Florbetapir SUVR 
ROIs (Bates et al., 2015). The [18F]-Florbetapir SUVR dataset across the DLB subjects was first subjected to 
a principal component analyses (PCA) in order to identify the composite factors that represent the dominant 
topography of [18F]-Florbetapir SUVR in the DLB sample (i.e. the weighted combination of Aβ binding in 
brain regions that account for the most variance across the DLB subjects). The resulting score for each DLB 
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subject could be interpreted as a data-driven composite measure of [18F]-Florbetapir SUVR (Supplementary 
Fig. 1). Subsequently, the amyloid PCA was correlated with regional cortical thickness (68 ROIs), total 
hippocampus, CA1 and subiculum while adjusting for age and total intracranial volumes for subcortical 
volumes. The a priori selected hippocampal ROIs were the total hippocampus, CA1 and the total subiculum. 
To account for multiple correlations, the statistical threshold for significance was set at the Benjamini-
Hochberg False Discovery Rate adjusted (FDR) level of p < 0.05 (i.e. across 68 ROIs for cortical thickness). 
The statistical significance threshold was set to p < 0.05 for all other tests. 
 
3. RESULTS 
3.1. Clinical and demographic information 
The brief clinical and cognitive characteristics of the included sample are shown in Table 2. Both the DLB 
and healthy controls were well-matched in terms of age and gender. As expected, the DLB group scored 
significantly poorer on the ACER and worse on the UPDRS (p < 0.001). To determine whether the exclusion 
of 5 DLB subjects had a significant impact on the demographics and cognitive characteristics in the study 
sample, we also compared these variables in the full dataset and found similar results: Both the DLB and 
healthy control groups were still comparable in terms of age and gender, while MMSE and UPDRS remained 
significantly poorer in the DLB group (p < 0.001) (Supplementary Table 1). 
 
3.2. Vertex-wise comparisons 
Compared to the total sample of healthy controls (n = 20), the DLB group demonstrated significantly increased 
Aβ in widespread regions encompassing the frontal and temporo-parietal cortices (adjusted for age and Monte-
Carlo cluster-wise correction: p vertex-wise < 0.001, p cluster-wise < 0.05). Next, we compared cortical thickness in 
DLB relative to amyloid-negative healthy controls (n = 16). The DLB group showed significant 
cortical thinning predominantly in the temporal cortex (adjusted for age and Monte-Carlo cluster-wise 
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correction: p vertex-wise < 0.001, p cluster-wise < 0.05). Both the uncorrected and corrected vertex-wise contrast 
maps are shown in Figure 1. 
 
 
Fig 1. Vertex-wise comparison of [18F]-Florbetapir SUVR and cortical thickness in DLB against healthy 
controls. A: Compared to controls, DLB showed significantly increased accumulation of Aβ in multiple 
cortices spanning the frontal and temporo-parietal regions. B: Compared to healthy controls, cortical thinning 
in DLB was restricted to the temporal regions. 
 
3.3. Comparison of total hippocampus and hippocampal subregions  
After accounting for age and intracranial volumes, the DLB group showed significantly smaller volumes 
relative to the amyloid-negative healthy controls in the hippocampus (p<0.01) and CA1 (p=0.02) and while 
subiculum differences approached trend (p = 0.06) (Fig. 2). 
 
 
Fig. 2. Boxplot of total volumes in the hippocampus, CA1 and subiculum in DLB and healthy controls. 
Abbreviations: HC = healthy controls, DLB = dementia with Lewy bodies; CA1 = cornu ammonis 1. 
HC DLB
4500
5000
5500
6000
6500
7000
7500
8000
V
o
lu
m
e
Hippocampus
HC DLB
900
1000
1100
1200
1300
1400
1500
V
o
lu
m
e
CA1
HC DLB
1000
1200
1400
1600
1800
2000
V
o
lu
m
e
Subiculum
Mapping Aβ on atrophy in DLB 
 11 
 
3.4. Global relationship between Aβ and cortical thinning 
Mixed effect models showed a weak but significant relationship between [18F]-Florbetapir SUVR and cortical 
thinning across the cortex in the DLB sample [β = -0.1, SE = 0.02, T = -5.3] (Fig. 3). The statistical significance 
of this global relationship was inferred from a chi-square comparison of the log-likelihood values against the 
reduced null model (p < 0.001). 
     
 
 
 
Fig. 3. Global relationship between amyloid and cortical thinning across the cortex. Each data point 
represents a subject-specific region-of-interest (ROI) from the Desikan-Killiany template (25 DLB subjects * 
68 ROIs for amyloid and cortical thickness across the whole brain) and coloured according to the cortical 
lobes. Mixed effect models revealed a modest but significant relationship between increased [18F]-Florbetapir 
SUVR and cortical thinning. 
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3.5. Principal component analysis of [18F]-Florbetapir in DLB and its association with grey 
matter atrophy 
Across the [18F]-Florbetapir SUVRs in the brain regions, PCA was first applied to reduce the dimensionalities 
of the [18F]-Florbetapir data into component topographies, effectively accounting for the high collinearity of 
the [18F]-Florbetapir data across ROIs. The PCA revealed a principal Aβ component that was characterised 
by positive regional loadings in the bilateral precuneus and frontal cortices (79% explained variance) (Fig. 4). 
We did not find any association of the Aβ principal component with regional cortical thickness after FDR 
correction. However, it was significantly associated with more severe hippocampal (r = -0.5, p FDR= 0.03) and 
subiculum atrophy (r = -0.6, p FDR = 0.01) after controlling for ICV and age (Fig. 5). To ensure that findings 
were robust across different techniques, we repeated the analyses using the MGX technique for partial volume 
correction and obtained consistent results (Supplementary Fig. 3). 
 
Fig. 4. Multivariate principal component analysis of [18F]-Florbetapir SUVR in DLB. The first identified 
component of Aβ in DLB explained 79% of the variance. It is characterised by prominent loadings within the 
bilateral precuneus and frontal cortices, mirroring the characteristic topography of Aβ observed in sporadic 
AD. 
  
Mapping Aβ on atrophy in DLB 
 13 
 
  
 
Fig 5. Correlation between Aβ principal component and volume of hippocampal subfields. Across the 
DLB subjects, greater representation of the Aβ principal component was significantly correlated with smaller 
hippocampus and subiculum. No signification correlations were found with other subcortical structures. 
 
 
4. DISCUSSION  
Clarifying the in vivo relationships between Aβ and brain atrophy in DLB will help stratify at-risk persons, 
and identify vulnerable patients who would stand to benefit from future anti-amyloid therapies should they 
prove to be effective. To this end, we performed a thorough mapping of Aβ on grey matter atrophy in the 
largest sample of DLB patients to undergo amyloid PET imaging and structural MRI to date. Overall, our 
main findings demonstrated that (a) the spatial extent of abnormal Aβ accumulation is much wider than the 
spatial extent of cortical thinning, congruent with conceptual biomarker models that confer primacy of Aβ 
deposition with respect to brain atrophy; (b) the global topography of Aβ showed a modest overlap with 
cortical thinning across the brain; (c) at the regional level, however, Aβ is preferentially associated with 
hippocampal and subiculum atrophy – both of which are markers of early vulnerability in AD. These findings, 
along with others (Sarro et al., 2016), appear to support the therapeutic potential of emerging anti-Aβ 
treatments in DLB.  
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In our study, the integration of PET and structural MRI data afforded the opportunity to jointly compare the 
intensity and spatial profiles of abnormal Aβ and cortical thinning within the same DLB subjects against a 
group of healthy controls who were comparable in terms of age and gender. Our observations of increased Aβ 
aggregation spanning the inferior temporal, posterior parietal cortices and the medial frontal regions are in 
accordance with previous studies using the [11C]-PiB tracer (Gomperts et al., 2012, 2008), and together 
confirm that cortical Aβ is a common feature of DLB that can be detected in vivo. In contrast, the pattern of 
cortical thinning was constrained to the temporal cortex in our sample of DLB. Indeed, the stark disparity 
between the spatial extent of Aβ accumulation and cortical thinning is in keeping with the biomarker model 
in AD (Jack et al., 2013).  
 
Set against the putative model of disease progression in AD, we aimed to determine the global overlap between 
Aβ burden and cortical thinning by using mixed effect models. Interestingly, our whole-brain, inter-regional 
analyses showed that elevated Aβ binding was associated with cortical thinning particularly in the temporal 
lobe (Fig. 3), where a focal cluster of significant atrophy was found in DLB compared to healthy controls 
(Fig. 1). Bearing in mind the absence of a longitudinal design in the present study, it is conceivable that the 
cortical distribution of antecedent Aβ may shape downstream patterns of cortical thinning in DLB, with the 
temporal lobe being the most susceptible to the neurotoxicity induced by early Aβ. Nevertheless, the weak 
effect size of the mixed effect model hints that other pathological factors – such as tau and Lewy bodies – may 
still influence atrophy to a larger degree than Aβ deposits.  
 
After establishing the topological overlap between increased Aβ binding and cortical thinning, we aimed to 
determine the extent to which the overall intensity of Aβ is correlated with regional cortical thickness in DLB. 
Multivariate PCA was first used to identify the most dominant pattern of Aβ in our DLB sample. Unbiased 
against anatomical definitions, multivariate techniques such as PCA evaluate the covariance structure of the 
PET data across brain regions rather than proceeding on a region-by-region basis (i.e. conventional univariate 
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analyses). The principal Aβ component was characterised by higher loadings within the bilateral precuneus 
and frontal cortices, remarkably mirroring the stereotypical distribution of Aβ in sporadic AD (Brier et al., 
2016). This suggests a similar cortical pattern of Aβ binding in DLB and AD, even though absolute levels of 
Aβ are typically less severe in DLB relative to AD (Donaghy et al., 2015). Consistent with a previous study 
(Shimada et al., 2016), we did not observe any robust correlations between Aβ and regional cortical thinning. 
However, the Aβ component was inversely associated with hippocampal and subiculum atrophy – both of 
which are widely recognised as early structural biomarkers of AD (de Flores et al., 2015; Mak et al., 2017a). 
This subiculum finding is especially noteworthy considering the growing research interest in hippocampal 
subfields, which may provide unique disease-related insights beyond the total hippocampus (Firbank et al., 
2010; de Flores et al., 2015; Mak et al., 2017b). Indeed, the subicular complex was previously reported as the 
earliest marker of AD (Carlesimo et al., 2015). Taken together with our findings, DLB patients with greater 
manifestation of the principal Aβ component are more likely to exhibit atrophy patterns associated with early 
AD. These findings also confirmed previous reports where higher cortical Aβ was associated with greater 
temporal lobe atrophy (Sarro et al., 2016; Shimada et al., 2016). Furthermore, the absence of correlations 
between the Aβ component and other subcortical structures guard against the possibility that our correlational 
findings are merely reflecting a generalised pattern of Aβ-associated atrophy. 
 
Nevertheless, these cross-sectional correlations should not be taken as evidence for a sole contribution of Aβ 
to drive atrophy in DLB. Indeed, several lines of research indicate that such conclusions may be 
oversimplified: (a) previous autoradiographic analysis in AD has reported intense tau inclusions ([11C]-PBB3 
ligand) in the subiculum without noticeable binding of [11C]-PiB (Maruyama et al., 2013); (b) we have 
previously reported that NFTs predicted medial temporal lobe atrophy independent of Aβ plaques in DLB 
cases (Burton et al., 2009); (c) in vivo studies in preclinical AD have reported that CSF tau modulates the 
relationship between Aβ and brain atrophy (Fortea et al., 2014). Furthermore, given the limited spatial 
resolution of PET, we could not determine whether hippocampal and subiculum atrophy are associated with 
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focal [18F]-Florbetapir binding within the same regions. Therefore, considering the growing body of evidence 
implicating early hippocampal and subiculum atrophy in AD (see de Flores et al., 2015 for a systematic 
review), the present findings may reflect an early process of AD-like atrophy emerging from the synergistic 
interactions of Aβ and NFTs. Ultimately, longitudinal designs with serial PET imaging of Aβ and NFTs will 
be necessary to validate this hypothesis. 
 
5. CONCLUSION 
Understanding the role of Aβ in people with DLB during life has implications for patient stratification, as well 
as the optimal design of clinical trials assessing anti-amyloid therapies. In the first report of its kind in DLB, 
our study demonstrated an association of Aβ with hippocampal and subiculum atrophy in DLB. We propose 
that Aβ maps onto atrophy in susceptible regions that are amongst the first to undergo neurodegeneration in 
AD, and concur with previous recommendations for investigating the efficacy of anti-Aβ therapeutics in 
people with DLB (Gomperts, 2014; Sarro et al., 2016; Shimada et al., 2013). Despite the high-profile failures 
of anti-Aβ treatments in people with AD, there are several reasons as to why DLB patients may stand to benefit 
from such treatments. First, it is well-established that macroscopic neurodegeneration is relatively milder in 
DLB compared to AD (Mak et al., 2015a; Nedelska et al., 2015). To the extent that the effectiveness of disease-
modification depends on the preservation of brain structure, it is conceivable that treatments may work better 
in DLB than in AD, where irreversible and extensive brain atrophy may pose insurmountable challenges for 
any drug to induce meaningful cognitive benefits. Taking a long-term perspective, future progress in disease-
modification trials for AD may also be generalizable for people with DLB, since there is emerging evidence 
– such as those provided in this study and others –  arguing that co-existent Aβ is not a benign process in DLB, 
but one that may be associated with an AD-type of brain atrophy. Thirdly, clinical trials are warranted to 
establish whether anti-Aβ treatments could be recommended as an additional intervention as a part of a multi-
combinatorial treatment strategy targeting various aspects of DLB. Moving forward, future studies 
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incorporating multi-PET imaging for tau and alpha-synuclein would be critical to disentangle the respective 
contributions of different pathologies to the multifaceted clinical picture of DLB. 
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Authors  Sample 
characteristics  
Study design and 
imaging analyses 
Summary of main 
findings 
Shimada et al., 
2013 
17 HC 
Age: 68, MMSE: 28 
 
8 DLB, 7 PDD 
Age: 73, MMSE: 22 
 
13 AD  
Age: 76, MMSE: 20 
 
Cross-sectional 
analysis 
 
Voxel-based 
morphometry 
 
Partial volume was 
not performed on 
[11C]-PiB data 
Aβ+ DLB/PDD 
subjects showed 
parahippocampal, 
lateral temporal and 
parietal atrophy. 
 
Aβ- DLB/PDD did 
not exhibit significant 
atrophy. 
 
Mean [11C]-PiB 
SUVR did not 
correlate with voxel-
wise grey matter 
maps. 
 
Sarro et al., 2016 20 DLB 
Age: 70, MMSE: 22 
Longitudinal within-
group design 
 
Time between MRI 
scans: 2.5 years 
 
ROI analysis 
between global 
[11C]-PiB uptake and 
rate of atrophy in 
grey matter ROIs, 
controlled for age 
Higher baseline 
[11C]-PiB SUVR was 
associated with 
accelerated GM 
atrophy over time in 
multiple regions, 
such as the posterior 
cingulate cortex, 
medial temporal lobe, 
occipital lobe, 
caudate and putamen, 
and ventricular 
enlargement 
 
Table 1. Summary of main findings from previous studies investigating the association of 
[11C]-PiB binding to grey matter atrophy in DLB. Abbreviations: Aβ = beta-amyloid; HC = 
Healthy controls; DLB = Dementia with Lewy bodies; PDD = Parkinson’s disease with 
dementia; VBM = Voxel-based morphometry; ROI = Region of interest; MMSE = Mini-mental 
state examination; MRI = Magnetic resonance imaging; PiB = Pittsburgh Compound B. 
 
 
 Controls (n=20) DLB  
(n=25) 
P value 
Age 75.9 ± 7.3 75.4 ± 6.8 0.8 † 
Gender (male:female) 16:4 21:4 0.7 c 
ACER 94.8 ± 3.02 65 ± 15.2 < 0.001 r 
UPDRS 5.6 ± 3.5 41.5 ± 19.0 < 0.001 r 
Disease duration (months) n/a 19.4 ± 13.5   
Aβ positivity  4 13  
 
Table 2. Brief demographics and cognitive characteristic of the study sample. 
Abbreviations: ACER = Addenbrooke’s Cognitive Examination Revised, UPDRS = Revised 
Unified Parkinson’s disease Rating Scale Motor Sub-scale; DLB = Dementia with Lewy 
bodies; † = Student’s T-Test; C = Chi-squared test; R = Rank-sum test. 
 
N Total DLB Healthy Controls P value 
Age 75.7 ± 6.7 75.9 ± 7.3 0.9 T 
Gender 25:5 16:4 NS C 
ACER 63.6 ± 15.6 94.8 ± 3.02 <0.001 R 
UPDRS 42.9 ± 18.4 5.6 ± 3.5 <0.001 R 
 
Supplementary Table 1. Brief demographics and cognitive characteristic of the study sample. 
Abbreviations: ACER = Addenbrooke’s Cognitive Examination Revised, UPDRS = Revised Unified 
Parkinson’s disease Rating Scale Motor Sub-scale; DLB = Dementia with Lewy bodies; T = 
Student’s T-Test; C = Chi-squared test; R = Rank-sum test. 
 
 
 
 
Supplementary Fig. 1. Left: PCA was performed on the dataset of [18F]-Florbetapir in the DLB 
group. Middle: Scree plot showing the explained variance for each component. Right: The 
subject-specific Aβ PCA scores for each DLB subject are subsequently used in our correlational 
analyses with regional cortical thickness and subcortical volumes. Because of the point of 
inflection on the scree plot after the first component, we restricted our focus to the first PCA in 
all subsequent analyses. 
 
 
 
 
Supplementary Fig. 3. Similar findings were obtained using the MGX technique for partial 
volume correction. Amyloid PCA was significantly associated with total hippocampus and 
subiculum volumes. Abbreviation: MGX = Muller Gartner Extended, PCA = Principal component 
analysis. 
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